Tolvaptan for the Treatment of Refractory Ascites
Masayuki Kurosaki, Namiki Izumi
openaire +3 more sources
The management of polycystic liver disease by tolvaptan
Masaki Kitajima+2 more
openaire +3 more sources
Potential amelioration of liver function by low-dose tolvaptan in heart failure patients. [PDF]
Mino Y+8 more
europepmc +1 more source
MP052THE USEFULNESS OF TOLVAPTAN IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE WITH CHRONIC KIDNEY DISEASE STAGE G3 TO G4 [PDF]
Kazunori Yamada+11 more
openalex +1 more source
Autosomal Dominant Polycystic Kidney Disease-Related Multifocal Renal Cell Carcinoma: A Narrative Iconographic Review. [PDF]
Sergi CM, Guerra L, Hager J.
europepmc +1 more source
Effectiveness of Tolvaptan for Autosomal Dominant Polycystic Kidney Disease in US Clinical Practice With Comparison to Historical Control Data. [PDF]
Perrone RD+9 more
europepmc +1 more source
Effects of tolvaptan on urine output in hospitalized heart failure patients with hypoalbuminemia or proteinuria [PDF]
Koji Takagi+13 more
openalex +1 more source
A secondary analysis of concurrent use of metformin and tolvaptan in ADPKD tolvaptan trials
I. Kitty Stanley+6 more
openaire +2 more sources
Tolvaptan: Clinical Evidence for Slowing the Progression of Autosomal Dominant Polycystic Kidney Disease [PDF]
Riccardo Magistroni
openalex +1 more source